Freedom of information (FOI) releases from OUH

This is a disclosure log of Oxford University Hospitals NHS Foundation Trust's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters

  • Keywords filters

  • Year filters

  • Month filters

89 disclosures

  1. F25-870 FOI SPECT/CT

    1. The manufacturer & model name of each gamma camera (Nuclear Medicine imaging system) & SPECT/CT system installed in or owned/managed by your Trust

     

    2. The hospital name where each system is installed

     

    3. The date that the current service/maintenance contract on each device started (if there is a multi year contract, please provide the date the multi year contract started)

     

    4. The date that the current service/maintenance contract on each system expires (if a there is a multi year contract, please provide the date the multi year contract will end)

      

    5. Please confirm the name and email address of the person we should contact if our company wishes to be considered for any of the service contracts prior to them coming up for renewal.

    a. If the contract is under a managed equipment service scheme, please let me know the name of the Company that holds the MES.

     

    Published: 13 August 2026

  2. Band 7 sonographer RRP payment reduction

    Please provide copies of any papers, reports, minutes, business cases, consultation documents, review documents, action logs, implementation plans, decision records, briefing papers, recommendations, or correspondence relating to the review and reduction of Recruitment and Retention Premia (RRP) for Band 7 Sonographers at Oxford University Hospitals NHS Foundation Trust from 1 January 2024 onwards.

    This request includes documents relating to:

    1. the review, consultation, amendment, reduction, continuation, implementation, or planned implementation of RRP for Band 7 sonographers in radiology, imaging, diagnostics, ultrasound, maternity and/or obstetric ultrasound services;

    2 the decision to reduce sonographer RRP from 15% to 12%, including any evidence, rationale, benchmarking, labour market analysis, sustainability or affordability assessment, equality/equity considerations, vacancy or recruitment data, and any review undertaken in line with NHS Terms and Conditions of Service;

    3 any consultation or implementation activity relating to sonographer RRP between April 2025 and November 2026, including (but not limited to) consultation meetings, decision notifications, implementation planning, and six-month review arrangements;

    4 any records held by Trust Management Executive (TME), Pay Panel, Workforce/HR governance, divisional workforce governance, radiology/imaging/diagnostics services, maternity services, or Trust Board governance concerning sonographer Recruitment and Retention Premia.  

    Published: 12 August 2026

  3. Percentage and number of Whipple operations carried out for Pancreatic Cancer

    1. Please confirm the number of Whipple Operations carried out between 2000 and today’s date, that have been completed and the patient has been told after that they DID NOT have Cancer but had the procedure was carried out anyway

    Published: 12 August 2026

  4. Recorded Assurance for Software Based Data Erasure of End of Life IT Equipment

    Under the Freedom of Information Act 2000, please provide the following recorded information held by your organisation regarding assurance processes for software based data erasure of end of life IT equipment. For clarity, this request relates specifically to the erasure of storage media associated with end of life hardware such as laptops, desktops, servers, storage arrays, or other data bearing IT equipment. It does not relate to operational deletion of data within live systems, routine account management, or DSP Toolkit self assessment processes. Physical destruction methods such as shredding, crushing, degaussing, or disintegration are outside the scope of this request. This request concerns software based erasure only. This request seeks to distinguish between confirmation that an erasure process was carried out and recorded evidence demonstrating that the final data state of a specific storage device is irrecoverable. I am not seeking technical configuration detail or security sensitive information, only the recorded assurance basis relied upon when concluding that personal data has been rendered irrecoverable.

    Please confirm:

    1) Whether your organisation’s policies, contractual terms, or internal procedures require an explicit outcome based warranty or guarantee that personal data on a specific storage device has been rendered irrecoverable as a final data state following software based erasure.

    2) Where software based erasure of storage media is undertaken internally, what recorded evidential assurance is relied upon to conclude that the final data state of the specific storage device is irrecoverable, as distinct from confirmation that an erasure process was executed.

    3) Where software based erasure is undertaken by a third party provider:

    a. Do the certificates or contractual documents held constitute an explicit outcome based warranty or guarantee of irrecoverability for each specific storage device processed?

    b. Beyond reliance on supplier accreditation or recognised standards including but not limited to ADISA certification, ISO accreditation, NIST alignment, HMG IA standards, NHS Digital guidance, or Data Security and Protection Toolkit assertions, and beyond confirmation that a wiping process was completed, does the organisation hold any recorded, device specific documentation evidencing independent verification, testing, or validation that the data on the storage media has been rendered irrecoverable in practice?

    4) If no explicit outcome based warranty or device specific outcome evidence is held beyond certification, accreditation, or confirmation of process completion, please confirm what recorded form of evidential assurance is relied upon when concluding that personal data has been rendered irrecoverable.

    Published: 10 August 2026

  5. Aquariums

    1. Existing Aquariums Please confirm whether the Trust currently owns or operates any ornamental aquarium(s) or aquatic displays. If yes, please provide: The number of aquariums currently in operation. Their general location (e.g. reception, children's ward, outpatient department, waiting area). The approximate year each aquarium was installed.

    2. Installation Supplier For each aquarium, please provide: The company that supplied and/or installed the aquarium. Whether the installation was procured via a tender or procurement framework or a direct award (and, if applicable, the name of the framework).

    3. Maintenance Please confirm: Whether aquarium maintenance is carried out in-house or by an external contractor. If externally maintained: Name of the contractor. Contract start date. Contract expiry or renewal date. Approximate annual contract value.

    4. Future Projects Please confirm whether the Trust currently has any plans, approved projects or budget allocations for new aquarium installations, replacements or refurbishments within the next 24 months.

    5. Procurement Please provide: The department responsible for procuring aquarium installations and maintenance. The job title of the person or team responsible.

    6. Expenditure Please provide, where available: Total expenditure on aquarium installations over the previous five financial years. Annual expenditure on aquarium maintenance for each of the previous five financial years.

    7. Supporting Documentation Please provide copies of any business cases, reports, evaluations or studies relating to the installation of aquariums, including any documents discussing patient wellbeing, staff wellbeing, visitor experience or therapeutic benefits.

    Published: 9 August 2026

  6. Usage of medicines in secondary care

    Dear Freedom of Information Office, I am conducting an analysis on the usage of medicines in secondary care and kindly request your help. I would be grateful if you could send me two datasets from your Trust, to inform this analysis:

    (1) SACT Cancer report An extract from the chemotherapy ePMA system showing patients treated by drug and diagnosis, as specified in table 1 (below).

    (2) Drug Patient Level Contract Monitoring (DrPLCM) report  Data fields from the DrPLCM report, as specified in table 2 (below).  Please do not send patient IDs or cost data, as I appreciate this would compromise data privacy and commercial sensitivity. 

    (3) Additionally, please could you let me know:

    3a. Which version of SACT is your Trust’s data sourced from: V2, V3, or V4?

    3b. Is the Trust actively using SACT V4? Yes/No Please email your response by reply with the data in .csv or Excel format and feel welcome to contact me if you have any questions about this request.

    Thank you in advance for your assistance. Appendices – specifications Please include the data fields specified within table 1 and table 2: 1. SACT Cancer report An extract of records from the chemotherapy ePMA system dated between 1st October 2025 and 30th June 2026, or to the latest date for which data is available, for all solid tumour and haematology malignancies (ICD-10 primary diagnosis codes C* and D*) Source: NHS Digital, NHS Data Model and Dictionary, Systemic Anti-cancer Therapy Data Set

    https://www.datadictionary.nhs.uk/data_sets/clinical_data_sets/systemic_anti-cancer_therapy_data_set.html Organisation code (code of provider) Organisation identifier (of SACT administration) Consultant code (initiated systemic anti-cancer therapy) Care professional main specialty code (start systemic anti-cancer therapy) Primary diagnosis (ICD-10 3rd or 4th digit) Morphology (ICD-O) TNM stage Adjunctive therapy type Regimen treatment intent Drug Regimen Start date (systemic anti-cancer therapy drug regimen) Clinical trial indicator Drug name Actual dose Unit of measure Route of administration Cycle number Number of planned cycles SACT administration date Regimen modification indicator Curative treatment completed as planned Non-curative treatment patient benefit indicator Toxicity modification indicator 2. Drug Patient Level Contract Monitoring (DrPLCM) report   An extract of records from this report for all hospitals in the Trust dated between 1st January 2026 and 30th June 2026   Sourced from the online NHS Data Model and Dictionary 

    https://archive.datadictionary.nhs.uk/DD%20Release%20May%202024/data_sets/supporting_data_sets/drugs_patient_level_contract_monitoring_data_set.html    Field number  Data Element  1  FINANCIAL MONTH  2  FINANCIAL YEAR  4  ORGANISATION IDENTIFIER (CODE OF PROVIDER)  5  ORGANISATION SITE IDENTIFIER (OF TREATMENT)  8  ORGANISATION IDENTIFIER (CODE OF COMMISSIONER)  19  ACTIVITY TREATMENT FUNCTION CODE  20  HOSPITAL PROVIDER SPELL IDENTIFIER  21  OUT-PATIENT ATTENDANCE IDENTIFIER  22  CLINICAL INTERVENTION DATE (DRUG DISPENSED)  23  THERAPEUTIC INDICATION CODE (SNOMED CT)  26  DRUG NAME (HIGH COST TARIFF EXCLUDED DRUG)  27  ROUTE OF ADMINISTRATION (SNOMED CT DM+D)  28  DRUG STRENGTH (HIGH COST TARIFF EXCLUDED DRUG)  29  DRUG VOLUME (HIGH COST TARIFF EXCLUDED DRUG)  30  DRUG PACK SIZE (HIGH COST TARIFF EXCLUDED DRUG)  31  DRUG QUANTITY OR WEIGHT PROPORTION (HIGH COST TARIFF EXCLUDED DRUG)  32  UNIT OF MEASUREMENT (SNOMED CT DM+D)  33  DISPENSING ROUTE (HIGH COST TARIFF EXCLUDED DRUG)  34  PROVIDER REFERENCE NUMBER  35  COMMISSIONED SERVICE CATEGORY CODE  36  SERVICE CODE  37  NATIONAL CANCER DRUGS FUND FORM CODE  43  LOCAL CONTRACT CODE  44  LOCAL CONTRACT CODE DESCRIPTION  45  LOCAL CONTRACT MONITORING CODE  46  LOCAL CONTRACT MONITORING DESCRIPTION  47  CONTRACT MONITORING ADDITIONAL DETAIL  48  CONTRACT MONITORING ADDITIONAL DESCRIPTION  52  VALUE ADDED TAX CHARGED INDICATOR (CONTRACT MONITORING) 

    Published: 31 July 2026

  7. Cancers Treatments

    I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of April 2026 to the end of June 2026, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

    Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2026 and the end of June 2026, or latest 3-months for which data are available?  Name of medicine    Number patients treated  1.1 Niraparib (Zejula)      1.2 Rucaparib (Rubraca)      1.3 Olaparib (Lynparza)      1.4 Cemiplimab (Libtayo) 1.5 Mirvetuximab soravtansine (Elahere)  

    Q2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?   Name of medicine      Number patients treated   2.1 Olaparib for all ovarian, fallopian tube or primary peritoneal cancers       2.2 Olaparib + bevacizumab       2.3 Olaparib monotherapy          2.4 Bevacizumab or all ovarian, fallopian tube or primary peritoneal cancers       2.5 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin         2.6 Bevacizumab monotherapy        

    Q3.  How many patients were treated with rucaparib (Rubraca) for the following indications in the 3 months between 1st April 2026 to the end of June 2026 or latest 3-months for which data are available?  Rucaparib Line of Therapy (indication) and NICE TA code    Number patients treated  3.1 1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055)      3.2 Relapsed platinum-sensitive ovarian cancer (TA1007)     

    Q4. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines in the 3 months between 1st April 2025 to the end of June 2026, or latest 3-months for which data are available?  Name of medicine    Number patients treated  4.1 Dostarlimab (Jemperli)      4.2 Pembrolizumab (Keytruda)      4.3 Lenvatinib (Lenvima)      4.4 Durvalumab (Imfinzi)

    Q5. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  Name of medicine    Number patients treated  5.1 Dostarlimab monotherapy     5.2 Dostarlimab in combination with Chemotherapy     5.3 Pembrolizumab monotherapy     5.4 Pembrolizumab + Lenvatinib in combination     5.5 Pembrolizumab in combination with Chemotherapy     5.6 Durvalumab with Carboplatin and Paclitaxel 5.7 Durvalumab monotherapy 5.8 Durvalumab + Olaparib combination

    Q6. How many patients with Endometrial Cancer (C54.1) received the following treatments by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? Name of combination or monotherapy dMMR Patients pMMR Patients 6.1 Dostarlimab + Carboplatin + Paclitaxel 6.2 Pembrolizumab + Carboplatin + Paclitaxel 6.3 Pembrolizumab + Lenvatinib 6.4 Dostarlimab as monotherapy at cycle 1 6.5 Dostarlimab as monotherapy maintenance (cycle 7+) 6.6 Pembrolizumab as monotherapy at cycle 1 6.7 Pembrolizumab as monotherapy maintenance (cycle 7+)

    Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  Tumour type   Number patients treated  7.1 Cutaneous Squamous Cell Carcinoma     7.2 Basal Cell Carcinoma     7.3 Non-small Cell Lung Cancer     7.4 Cervical Cancer    

    Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  Treatment intent   Number patients treated  8.1 Curative     8.2 Palliative    

    Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  Treatment intent   Number patients treated  9.1 Adjuvant    

    Published: 31 July 2026

  8. Procedure numbers

    I would be grateful if you could share the activity data for FY24–25 for the procedures listed below. Gynaecology Procedures

    1. Total Laparoscopic Hysterectomy • Q07* – Abdominal excision of uterus • Y75.2 – Laparoscopic approach to abdominal cavity NEC

    2. Total Robotic Hysterectomy • Q07* – Abdominal excision of uterus • Y75.3 – Robotic minimal access approach to abdominal cavity

    3. Endometriosis Excision • T33.1, T33.2 • T42.1, T42.2 • Q01.3, Q02.1, Q09.3 • Q16.1, Q17.1, Q17.4 • Q20.7 • Q25.1 • Q43.2, Q49.1 • Q52.1, Q52.2

    4. Laparoscopic Urogynaecology (Uterine/Vaginal Prolapse) • P22*, P23*, P24*, P28*, P30* • (+ Y75.2 where performed laparoscopically)

    5. Open Myomectomy • Q09.2 – Open myomectomy

    6. Abdominal Hysterectomy • Q07* – Abdominal excision of uterus

    7. Open Urogynaecology (Uterine/Vaginal Prolapse) • P22*, P23*, P24*, P28*, P30*

    8. Caesarean Section • R17* – Elective caesarean delivery • R18* – Other caesarean delivery (including emergency cases) Plastics Procedures

    9. Breast Augmentation • B31.2 – Augmentation mammoplasty • B30.1 – Insertion of prosthesis of breast NEC

    10. Abdominoplasty • S02.1 – Abdominoplasty 11. DIEP Flap Reconstruction • B39.3 – Reconstruction of breast using free deep inferior epigastric perforator flap NEC • B39.7 – Reconstruction of breast using bipedicled free deep inferior epigastric perforator flap

    Published: 31 July 2026

  9. Adults with Learning Disabilities

    I am requesting information regarding supported living and residential care services for adults with a primary support need of learning disabilities (LD). Long term care is provided to clients on an ongoing basis and has been allocated on the basis of eligibility criteria / policies (i.e. an assessment of need has taken place) and are subject to regular review.

    Please refer to the following link for further clarification, if needed (https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/social-care-collection-materials-2024/salt-data-return-2023-2024-guidance/lts001a).

    Supported living may also be called Supported accommodation or Supported housing and is a housing scheme where housing, support and care services are provided to help people with disabilities live as independently as possible in the community.

    Total placements is the total number of active funded placements in that period, included those carried over from previous years. New placements are those newly commissioned in that period only, ie not carried over from a previous year.

    Please respond using the attached excel template. For financial year FY26, please provide the full year figure as at the date of your response.

    For financial year FY27, please provide a forecast or budgeted number of placements if available.

    1. Residential Care: Please provide the total number of adults (aged 18-64) with a primary support need of LD in long-term residential care funded by the TRUST, in the following periods, broken down by the following weekly fee bands: £3,000 to £4,999 per week; £5,000 to £6,999 per week; £7,000 or more per week • Financial year 2021/22 (FY22) • Financial year 2022/23 (FY23) • Financial year 2023/24 (FY24) • Financial year 2024/25 (FY25) • Financial year 2025/26 (FY26) – Year to Date • Financial year 2026/27 (FY27) – budgeted / forecast

    2. Residential Care: Please provide the number of new placements made for adults (aged 18-64) with a primary support need of LD in long-term residential care funded by the TRUST in the following periods, broken down by the same weekly fee bands: £3,000 to £4,999 per week; £5,000 to £6,999 per week; £7,000 or more per week • Financial year 2021/22 (FY22) • Financial year 2022/23 (FY23) • Financial year 2023/24 (FY24) • Financial year 2024/25 (FY25) • Financial year 2025/26 (FY26) – Year to Date • Financial year 2026/27 (FY27) – budgeted / forecast

    3. Supported Living: Please provide the total number of adults (aged 18-64) with a primary support need of LD in long-term supported living funded by the TRUST, in the following periods, broken down by the following weekly fee bands: £3,000 to £4,999 per week; £5,000 to £6,999 per week; £7,000 or more per week • Financial year 2021/22 (FY22) • Financial year 2022/23 (FY23) • Financial year 2023/24 (FY24) • Financial year 2024/25 (FY25) • Financial year 2025/26 (FY26) – Year to Date • Financial year 2026/27 (FY27) – budgeted / forecast

    4. Supported Living: Please provide the number of new placements made for adults (aged 18-64) with a primary support need of LD in long-term supported living funded by the TRUST in the following periods, broken down by the same weekly fee bands: £3,000 to £4,999 per week; £5,000 to £6,999 per week; £7,000 or more per week • Financial year 2021/22 (FY22) • Financial year 2022/23 (FY23) • Financial year 2023/24 (FY24) • Financial year 2024/25 (FY25) • Financial year 2025/26 (FY26) – Year to Date • Financial year 2026/27 (FY27) – budgeted / forecast

    Published: 30 July 2026

  10. Inpatient treatment after circumcision

    1.Please can you tell me the number of boys aged 0-18 who have received inpatient treatment for haemorrhage, shock or sepsis which relates to a circumcision between January 1 2020 and May 1 2026.

    a. Please provide this information broken down by year.

    Published: 23 July 2026